New shot could help lower stubborn high cholesterol
NCT ID NCT07253584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested an injectable drug called SAL003 in 720 adults with high cholesterol or mixed dyslipidemia. Participants were already on statins but still had high LDL cholesterol. The study compared SAL003 to a placebo to see if it safely lowers cholesterol further. The main goal was the percent change in LDL cholesterol after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAL003 (an anti-PCSK9 monoclonal antibody injection)
What this could lead to
If successful, SAL003 could offer a new option to lower stubborn high cholesterol when statins alone aren't enough, potentially reducing heart disease risk.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not show enough benefit over placebo, or side effects could limit its use. It's also an add-on to statins, not a standalone treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS, HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi’an, Shanxi, China